Veracyte, Inc. - Common Stock (NQ:VCYT)

43.64 -0.38 (-0.86%)

Delayed Quote Updated: 1:44 PM EDT, Oct 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Veracyte, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Despite its growth, VERACYTE INC (NASDAQ:VCYT) remains within the realm of affordability. ↗

April 12, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

New Data Demonstrate Accuracy of Veracyte’s Whole-Genome Sequencing-Based MRD Testing Platform for Muscle-Invasive Bladder Cancer

March 25, 2025

From Veracyte, Inc.

Via Business Wire

While growth is established for VERACYTE INC (NASDAQ:VCYT), the stock's valuation remains reasonable. ↗

March 22, 2025

NASDAQ:VCYT is scoring great on several growth aspects while it also shows decent health and profitability. At the same time it remains remains attractively priced.

Via Chartmill

A Glimpse Into The Expert Outlook On Veracyte Through 5 Analysts ↗

February 25, 2025

Via Benzinga

Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock. ↗

February 06, 2025

A fundamental and technical analysis of (NASDAQ:VCYT): Is VERACYTE INC (NASDAQ:VCYT) suited for high growth investing?

Via Chartmill

Demystifying Veracyte: Insights From 7 Analyst Reviews ↗

January 29, 2025

Via Benzinga

5 Analysts Assess Veracyte: What You Need To Know ↗

March 20, 2025

Via Benzinga

Veracyte Announces Eight Abstracts Highlighting Performance and Clinical Utility of Its Decipher and MRD Tests in Urologic Cancers To Be Presented at EAU25

March 19, 2025

From Veracyte, Inc.

Via Business Wire

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade ↗

March 12, 2025

Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.

Via Benzinga

VERACYTE INC (NASDAQ:VCYT) stands out as a growth opportunity that won't break the bank. ↗

February 27, 2025

Discover VERACYTE INC, an undervalued growth gem. NASDAQ:VCYT is shining in terms of growth metrics, and it's also displaying strong financial health and profitability, retaining an appealing...

Via Chartmill

Exploring NASDAQ:VCYT's high growth characteristics. ↗

January 14, 2025

Why VERACYTE INC (NASDAQ:VCYT) qualifies as a high growth stock.

Via Chartmill

Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing? ↗

December 18, 2024

Unlocking the high Growth Potential of VERACYTE INC (NASDAQ:VCYT).

Via Chartmill

Navigating 9 Analyst Ratings For Veracyte ↗

December 05, 2024

Via Benzinga

Diagnostic Company Veracyte Weighs Sale For French Subsidiary, Analyst Says 'Walking Away' Is A Long-Term Positive ↗

February 25, 2025

Veracyte topped Q4 earnings and revenue estimates as testing volume grew. The company is evaluating options for its French unit.

Via Benzinga

Veracyte Announces Fourth Quarter and Full Year 2024 Financial Results

February 24, 2025

From Veracyte, Inc.

Via Business Wire

Earnings Scheduled For February 24, 2025 ↗

February 24, 2025

Via Benzinga

Is NASDAQ:VCYT a Fit for high Growth Investing Strategies? ↗

November 22, 2024

Should you consider VERACYTE INC (NASDAQ:VCYT) for high growth investing?

Via Chartmill

Veracyte to Participate in Upcoming Investor Conferences

February 19, 2025

From Veracyte, Inc.

Via Business Wire

New Data at ASCO GU Show Power of Veracyte’s Decipher Tests to Improve Patient Care and Its GRID Tool to Advance Prostate and Bladder Cancer Research

February 14, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte Announces 17 Abstracts Demonstrating Its Decipher Tests’ Leadership in Urologic Cancers to Be Presented at the 2025 ASCO GU Symposium

February 11, 2025

From Veracyte

Via Business Wire

Breaking Down Veracyte: 4 Analysts Share Their Views ↗

October 10, 2024

Via Benzinga

New Study Shows Veracyte’s Decipher Bladder Test Predicts Disease Upstaging in Patients with Bladder Cancer

February 05, 2025

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Fourth Quarter and Full-Year 2024 Financial Results on February 24, 2025

February 04, 2025

From Veracyte, Inc.

Via Business Wire

Cathie Wood's Ark Invest Trims Palantir Again As Peter Thiel Co-Founded Firm's Stock Tumbles Nearly 15% In 2025 ↗

January 14, 2025

Cathie Wood-led Ark Invest sold 140,518 shares of Palantir and bought shares of Tempus AI Inc. The total value of the trades is about $9.1 million.

Via Benzinga

Topics Artificial Intelligence

Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines

December 05, 2024

From Veracyte, Inc.

Via Business Wire

Cathie Wood Sees $400B Opportunity In Biologics — How Have Her Bets Fared? ↗

November 26, 2024

Cathie Wood, CEO of ARK Invest, is doubling down on biologics, seeing unprecedented potential at the intersection of artificial intelligence, genetic sequencing, and gene editing technologies.

Via Benzinga

Topics Artificial Intelligence

Smaller Cap Biotechs Are In Season: How Are We Doing? ↗

November 07, 2024

SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range.

Via Talk Markets

Veracyte Announces Third Quarter 2024 Financial Results

November 06, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Participate in Upcoming Investor Conferences

October 30, 2024

From Veracyte, Inc.

Via Business Wire

Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024

October 16, 2024

From Veracyte, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.